Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.51 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067020 | 0.86 | CA12 (0.51) | SOS1CA12CA2ENPP1ENPP3 | |
| SCHEMBL6304328 | 0.85 | ENPP1 (0.52) | SOS1CA12CA2ENPP1ENPP3 | |
| SCHEMBL4126119 | 0.85 | AKR1C3 (0.55) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL22558454 | 0.85 | AKR1C3 (0.55) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL7916314 | 0.84 | TDP1 (0.67) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL3792465 | 0.84 | TDP1 (0.56) | CA12CA2ENPP1ENPP3ENPP2 | |
| SCHEMBL926461 | 0.83 | CA12 (0.51) | SOS1CA12CA2ENPP1ENPP3 | |
| SCHEMBL14138146 | 0.81 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 | |
| SCHEMBL9779005 | 0.81 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 | |
| SCHEMBL11519866 | 0.81 | SOS1 (0.70) | SOS1FFAR1FFAR4MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068180-B1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS | PFIZER PROD INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-0949246-B1 | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-0949245-B1 | Process for alkylating hindered sulfonamides | PFIZER PROD INC (US) | 2001-10-04 | — | — | EP | disclosed |
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | HAWKINS JOEL M (US) | 2001-08-02 | — | — | US | disclosed |
| CN-1296474-A | Alkylation of hindered sulfonamides for the preparation of matrix metalloproteinase inhibitors | PFIZER PROD INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6229025-B1 | MICHAEL ADDITION TO PROPIOLATES | PFIZER INC | 2001-05-08 | — | — | US | disclosed |
| CN-1288885-A | Alkylating method of hindered sulfonic acid | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
| EP-1068180-A1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS | Pfizer Products Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6118016-A | Process for preparing phenoxyphenylsulfonyl halides | PFIZER INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6114568-A | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors | PFIZER INC. (US) | 2000-09-05 | — | — | US | disclosed |
| CN-1238329-A | Process for preparing phenoxyphenylsulfonyl halides | PFIZER PROD INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1234396-A | Process for alkylating hindered sulfonamides | PFIZER PRODUCTS CO (US) | 1999-11-10 | — | — | CN | disclosed |
| WO-1999052862-A1 | PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0949245-A1 | Process for alkylating hindered sulfonamides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0949246-A1 | Process for preparing phenoxyphenylsulfonyl halides | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011143-A1 | Process for preparing phenoxyphenylsulfonyl halides | MMP2, MMP3, MMP14 | SOS1 3801/4885CA12 1251/4885CA2 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.